Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00520910|
Recruitment Status : Completed
First Posted : August 27, 2007
Results First Posted : June 18, 2019
Last Update Posted : June 18, 2019
|Condition or disease||Intervention/treatment||Phase|
|Aging Skin Abnormalities||Drug: Polypodium leucotomos||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing UVA Premutagenic and Photoaging Markers|
|Actual Study Start Date :||August 2007|
|Actual Primary Completion Date :||May 2009|
|Actual Study Completion Date :||May 2009|
Experimental: Polypodium leucotomos extract
Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
Drug: Polypodium leucotomos
Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
Other Name: Heliocare
No Intervention: No intervention
Subject is not given any treatment.
- Change in Common Deletion (CD) Value in DNA of Skin Biopsy Sample [ Time Frame: baseline, 24 hours ]CD is determined by semiquantitative real-time polymerase chain reaction.
- 8-oxo-7,8-dihydro-2'-Deoxyguanosine (8-oxo-dG) Quantification in Skin Biopsy Sample Taken From Final Visit [ Time Frame: 24 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00520910
|United States, Florida|
|University of Miami Skin Research Group Office|
|Miami, Florida, United States, 33136|
|Principal Investigator:||Brian Berman, M.D., Ph.D.||University of Miami, Department of Dermatology and Cutaneous Surgery|